The multifunctional growth factor transforming growth factor b (TGFb) is one of the most important ligands involved in modulation of cell behavior in ocular tissues. This includes modulation of cell migration and proliferation, cell death, and protein synthesis during development, tissue repair, and other physiological or pathological processes. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] In most cases, TGFb enhances extracellular matrix production and suppresses cell proliferation. Moreover, TGFb is capable of inducing a number of growth factors, that is, connective tissue growth factor (CTGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), and vascular endothelial growth factor (VEGF), as well as TGFb1 itself. 15, 16 All these factors have important roles in restoration of normal tissue following injury. Although three isoforms of TGFb, namely, TGFb1, b2, and b3, are present in mammalian tissues and in vitro experiments often elicit similar responses, their in vivo roles and expression are not uniform. Studies from gene knockout mice reveal the distinct role of these isoforms in embryonic development and tissue morphogenesis (as discussed later).
However, as in other tissues, overactivation of TGFb underlies the pathogenesis of wound healing-related fibrotic diseases in eye tissues, which impair vision and ocular tissue homeostasis ( Figure 1 ). In the present article, the recent literature is examined in regards to the role of TGFb and its signaling pathways in the pathogenesis of ocular disorders. We conclude that herapeutic strategies for such diseases may be devised by targeting the TGFb signaling pathway.
Cytokines and growth factors in aqueous humor of the eye
The aqueous humor that bathes the inner ocular structures (corneal endothelium, iris, crystalline lens, trabecular meshwork, and retina) contains various cytokines and growth factors. TGFb, especially TGFb2, is the predominant cytokine. Physiologically, TGFb is mainly produced in the ciliary epithelium and lens epithelium as a latent, inactive, form consisting of mature TGFb, the latency-associated peptide (LAP) (small latent form), and the latent-TGFb-binding protein (LTBP). [17] [18] [19] [20] [21] [22] [23] [24] Heterogeneous expression patterns of each TGFb isoform in the crystalline lens have been reported in humans and animals. 25 During the clinical course of various ocular diseases, the concentration of TGFb2 in the aqueous humor changes. For example, in an eye with proliferative vitreoretinopathy (PVR), a disorder of post-retinal detachment and retinal fibrosis, the concentration of TGFb2 in the vitreous humor increases in association with the progression of retinal fibrosis. The concentration of total and active TGFb2 is also higher in patients with diabetic retinopathy and open-angle glaucoma than in normal subjects. In diabetic retinopathy, chronic obstruction of retinal microvessels induces upregulation of VEGF and chemotaxis of macrophages, a potent source of TGFbs. VEGF and TGFb cooperate to induce both retinal neovascularization and fibrosis around these new vessels, which may potentially cause retinal detachment or bleeding. Increased TGFb2 levels induce matrix expression and deposition in trabecular meshwork cells, leading to obstruction of the aqueous drainage route and an increase of intraocular pressure in a glaucomatous eye. In each of these examples, TGFb plays a role in disease pathogenesis. In eyes with pseudoexforiation syndrome, a kind of glaucoma with deposition of exforiative material on the lens, iris, or trabecular meshwork, the level of TGFb1 increases, but the exact role of TGFb1 in the pathogenesis of this disease is unknown.
TGFb signal transduction
Upon TGFb binding to its receptor, signaling occurs through a pair of transmembrane receptor serinethreonine kinases and the downstream mediator Smad proteins. Receptor-activated Smad proteins, Smad2 and Smad3, are phosphorylated directly by the TGFb receptor type I kinase. They then partner with the common mediator, Smad4, and translocate to the nucleus where they play a prominent role in the activation of TGFb-dependent gene targets. Smad6/7 are known to be inhibitory Smads, which block phosphorylation of Smads2/3. 26, 27 However, the roles of Smad2 and Smad3 differ because the lack of Smad2 is lethal for mice at the embryonic stage, whereas those lacking Smad3 survive. 28 The bone morphogenetic proteins (BMPs), which are members of the TGFb superfamily, bind to their own receptors and phosphorylate Smads 1, 5, and 8 which then bind to Smad4 for translocation to the nucleus. Additionally, in some cell types, TGFb can potentially activate different arms of the mitogen-activated kinase (MAPK) pathway, including stress kinases (ie, c-Jun-N-terminal kinase, JNK), p38MAPK pathway, RhoA-related signals, phosphatase2A, 29 or PI3-kinase/AKT. [30] [31] [32] Although Smad2/3 signaling is relatively specific to the binding of ligands of the TGFb/activin family to cell surface receptors, investigators are discovering that MAPKs (p42/p44 Erk1/2, JNK, or p38MAPK) phosphorylate specific sites in the middle linker region of Smad2/3, sites that are distinct from the C-terminus that is phosphorylated by the TGFb II receptor (Figure 2) . [33] [34] [35] [36] Thus, ligands capable of activating MAPKs potentially modulate Smad signaling induced by TGFb. It has recently been demonstrated that p38MAPK activate phosphorylation of Smad3 in the middle linker region, which enhances Smad3/4 complex formation and nuclear translocation, 37 consistent with our finding of diminished Smad3/4 reporter gene activity in the presence of a p38MAPK inhibitor. Such phosphorylation by MAPKs in the Smad3 linker region is reportedly required for the full activation of Smad signaling. 38, 39 For example, inhibition of p38MAPK by the specific inhibitor SB202190 interferes with stimulatory effects of exogenous TGFb2 on migration of cells and on production of ECM components, such as collagen type I and fibronectin, while having no effects on the basal activity. Moreover, p38 MAPK may affect these end points not only by direct phosphorylation of the Smad proteins in the middle linker region 40 but also 
Embryogenesis and developmental disorders
Classical gene targeting techniques have provided important information about the role of each TGFb isoform in eye morphogenesis, although the mice also have various systemic abnormalities. Although a mouse embryo that lacks TGFb1 or TGFb3 does not have any ocular abnormalities, a mouse embryo lacking TGFb2 has multiple defects in ocular structures, that is, thin cornea with a loss of the corneal endothelium and anterior chamber, immature retina, and persistent vitreous vessels. [44] [45] [46] [47] [48] These findings may coincide with the fact that TGFb2 predominates in eye aqueous humor. Overexpression of TGFb1 by using a-crystalline promoter in TGFb2-null mice rescues the abnormalities in ocular development caused by the deletion of TGFb2. 49 Lens epithelial cells are of ectodermal origin. During embryonic development, surface ectoderm invaginates into the optic cup and the vesicle is separated from surface ectoderm on embryonic day 11.5 in the mouse. At this time, the cells also start to express vimentin, an intermediate cytoskeletal protein of mesenchymal cell types, but also retain their epithelial character by expressing the epithelial surface marker, cadherins. Then, the cells located in the posterior part of the lens vesicle start to express various crystalline proteins to form a transparent lens. Members of the FGF and BMP family are potent inducers of lens fiber differentiation. They are expressed in various ocular tissues, that is, retina, ciliary body, and lens cell themselves. The retina produces FGF and insulin-like growth factor (IGF) family members as potential fiber cell differentiation factors. The nuclei of elongating lens fiber cells are positive for phospho-Smad1, an indicator of signaling through BMP receptors. 50 These data indicate that BMPs participate in the differentiation of lens fiber cells, along with at least one additional, and still unknown factor. In mature lens fibers, the nuclei are degraded by apoptosis and this apoptotic process is also modulated by Smad signals. 50 In addition to BMPs, TGFbs are also involved in lens fiber differentiation. 50 Overexpression of dominant-negative forms of either type I or type II TGFb receptors in the lens fibers of transgenic mice using mouse aA-crystallin promoter results in the development of pronounced bilateral nuclear cataracts. The phenotype was characterized by attenuated lens fiber elongation in the cortex and disruption of fiber differentiation, culminating in fiber cell apoptosis and degeneration in the lens nucleus.
Although all three TGFb isoforms are expressed in cornea, the lack of any one of them does not affect embyonic morphogenesis/differentiation of corneal epithelium as examined by the expression pattern of cornea-specific cytokeratin, keratin 12. Additionally, loss of Smad3, a prominent TGFb-signaling molecule, does not produce ocular abnormalities, indicating that multiple signaling pathways are involved in ocular tissue morphogenesis.
TGFb signal transduction and tissue fibrosis
TGFb generally enhances gene expression related to tissue fibrosis in vivo and in vitro in mesenchymal cells in the eye. Details of differences between Smad2 and Smad3 were recently investigated using a gene expression array made of embryonic fibroblasts obtained from embryos lacking either Smad2 or Smad3. 51, 52 Expression of a-smooth muscle actin (aSMA), important in fibroblast-myofibroblast conversion, is mediated by Smad2. [53] [54] [55] However, expression of Snail, the master transcription factor involved in the earlier step of the epithelialmesenchymal transition (EMT), as an important step in the process of tissue fibrosis in the eye, is controlled by Smad3. 56 The expression of the majority of the extracellular matrix components and enzymes involved in matrix reorganization/ maturation depends on Smad3, whereas expression of matrix metalloproteinase-2 is Smad2 dependent. In Smad3-null mice, re-epithelialization is accelerated and fibrosis is reduced during tissue repair in skin. 57 However, blocking TGFb type II receptor function by dominant negative expression in collagen I-expressing fibroblasts in a transgenic mouse results instead in a paradoxical systemic tissue fibrosis in association with an uncontrolled Smad signaling activation. 58 The mechanism of this phenomenon could be explained the fact that Smad3 is phosphorylated by various MAPK at their middle linker region, which might promote nuclear translocation of Smad and might stimulate fibrosis-related gene expression.
Wound healing reaction in the lens and post-cataract surgery complications
The crystalline lens is a unique tissue, consisting of epithelial cells, lens fibers, and the anuclear lens content inside a specialized basement membrane, the lens capsule. Following cataract surgery or lens capsular injury, cuboidal lens epithelial cells undergo EMT and transdifferentiate to myofibroblasts, expressing aSMA on the residual lens capsular tissue (Figure 3) . [59] [60] [61] [62] [63] [64] [65] [66] Tissue fibrosis in association with EMT is also a key step in the process of fibrotic diseases in other tissues and organs, characterized by the presence of fibrous tissue accumulation and contraction by aSMA-expressing myofibroblasts. 67, 68 In this process, an epithelial cell changes its morphology and its transcriptional program to those characteristic of a mesenchymal cell type. Lens epithelium-derived myofibroblasts become capable of expressing components of the fibrous ECM and matrix-degrading enzymes. Structural and histological organization of postoperative capsular opacification is quite similar to that seen in healing tissue or tissue granulation formed around an implanted foreign body. Clinically, this fibrotic reaction in postoperative lens epithelium results in opacification and contraction of the residual lens capsule. Optical transparency is reduced, and implanted artifical intraocular lens (IOL) move off center, both of which decrease the patients' vision.
TGFb and Smad signaling in lens epithelium EMT
In the quiescent normal lens epithelial cell, Smads2/ 3 are detectable in the cytoplasm, indicating that the cells either are not or are minimally affected by endogenous TGFb through this signaling pathway, as they are not detectable in the nucleus. However, TGFb signaling is rapidly activated following wounding. 69 Following cataract surgery, Smad2/3 translocates to the nucleus prior to the appearance of aSMA-positive cells (heralding the ocurrence of EMT). Similarly, in mice, an injury in the anterior capsule induces Smads3/4 nuclear translocation within 12 h, being followed by expression of Snail and subsequent EMT in the lens epithelium. This Smad nuclear translocation was abolished by local administration of anti-TGFb2-neutralizing antibody. TGFb is the growth factor involved in EMT of lens epithelial cells in vivo, as has been shown for other epithelial cell types in vitro. For example, overexpression of TGFb1 in lens cells by transgenic techniques induces cataractous changes in the lens epithelial cells in association with EMT and accumulation of fibrous/collagenous extracellular matrix. 70, 71 Loss of Smad3 attenuates injury-induced EMT in the lens or renal epithelium. However, the suppression of EMT in lens epithelium seems to be dependent on the level of TGFb stimuli. Our unpublished data show that severe intraocular inflammation caused by corneal exposure to alkali is associated with EMT in lens epithelium even in Smad3-null mice, although the extent of EMT is much lower. Similarly, overexpression of active TGFb1 in lens epithelium using adenoviral gene introduction or transgenic technology induces EMT in lens epithelium in mice and this EMT (although to a lesser extent) is also seen in the absence of Smad3 (West-Mays J, personal communication, 2005). These findings suggest that upon uncontrolled stimulation by TGFb, lens epithelium is capable of undergoing EMT, possibly via signaling via other as yet unidentified molecules. Alternatively, Smad2 might bypass the loss of Smad3. Nevertheless, the involvement of Smad3 signal in lens epithelium EMT raises the possibility of therapies for EMT-related fibrotic diseases gene transfer of Smad7 or other molecules which are capable of blocking Smad signaling, that is, BMP-7, Id2 or Id3, as discussed below. 72 Other signaling cascades are also required for TGFb-induced EMT. 66, 73 Our unpublished data show that specific inhibitors of PI3-kinase or Rho kinase also suppress TGFb2-induced EMT of lens epithelium in organ culture.
PVR and retinal pigment epithelium (RPE)
PVR is a disease caused by the formation of fibrotic tissue on the detached retina, which reduces the flexibility of the retina and may potentially make it difficult to reattach the retina. RPE cells are normally located in the cell layer external to the retina. Following retinal break and detachment, RPE cells disseminate in the subretinal space and vitreous humor through the retinal break(s), and then settle on the luminal retinal surface following development of rhegmatogenous retinal detachment. 74 ,75 RPE cells then undergo transformation to fibroblast-like cells, proliferate, and produce TGFb in the eye S Saika extracellular matrix components, participating in this fibrotic sequelae. Muller glia cells are also involved in the fibrotic reaction of the detached retina.
As in the EMT-related fibrosis in the lens, TGFb can induce transformation of RPE cells to myofibroblast-like cells in vitro, [76] [77] [78] suggesting that TGFb is likely a key player in the development of PVR, although various other growth factors, including PDGF, HGF, and activin, are all reportedly involved in its pathogenesis. [79] [80] [81] [82] [83] [84] [85] The concentration of TGFb2 in the vitreous humor of the eye correlates with the severity of the PVR, underlying its importance. 
Gene introduction to suppress EMT and subsequent tissue fibrosis in lens or retinal pigment epithelia
Suppression of EMT might be beneficial to prevent or treat the lens capusar fibrosis that leads to fibrotic-type cataracts, or post-cataract surgery capsular opacification, both of which potentially reduce vision. Based on the finding that loss of Smad3 attenuates injury-induced lens epithelial EMT, we tested adenoviral gene introduction of cDNAs for Smad7, BMP-7, Id2 or Id3, all of which antagonize TGFb/Smad signal, in vivo to an injured mouse lens epithelium. While all of these genes attenuated injury-induced EMT of the lens epithelium, 86 Smad7 gave the greatest degree of inhibition of in vivo lens cell EMT.
Attenuation of injury-induced EMT of lens epithelial cells by Smad3 gene ablation or Smad7 gene introduction also suggests that such approaches might suppress EMT in RPE cells, and therefore prove beneficial in the treatment of PVR. Indeed, loss of Smad3 attenuates PVR in vivo, 87 and Smad7 gene introduction actually does suppress PVR in mice (S Saika, unpublished data, 2005).
Activation of Smads by phosphorylation at its middle linker region by MAPK is also a potential target of inhibition of TGFb signaling. It has been reported that p38MAPK is involved in EMT in cultured cells. A p38MAPK inhibitor reduces reporter gene expression using an Smad-dependent promoter, indicating that p38MAPK signal may be involved in Smad-dependent gene expression. Chemical inhibition of p38MAPK attenuates migration and ECM production of the RPE cell line, ARPE-19. 88 In vivo adenoviral gene transfer of dominantnegative p38MAPK suppresses the fibrotic reaction by RPE cells in an experimental mouse PVR model. 88 Further study is needed to establish the clinical application of this treatment strategy.
Roles of TGFb siganling in corneal wound healing
The cornea consists of a nonkeratinizing stratified epithelium, lying on Bowman's membrane, and a stroma consisting of collagenous lamellae and keratocytes (corneal fibroblasts) (Figure 4) . Although the cornea lacks vasculature, the main components are quite similar to those of the skin; stratified epithelium and a collagenous matrix containing mesenchymal cells lying beneath it. TGFb is expressed in corneal tissue. [89] [90] [91] [92] [93] [94] [95] [96] [97] An epithelial defect in the cornea must be rapidly resurfaced to avoid microbial infection and further damage to the underlying stroma. Healing of an epithelial defect is achieved by migration of epithelial cells, followed by an enhancement of cell proliferation for re-establishment of the epithelium stratification. Although there is some difference in the expression pattern of TGFb isoforms in the cornea, it is believed that TGFb is upregulated upon wounding. In mouse cornea, intracellular TGFb1 is detected in corneal epithelium, but extracellular, secreted TGFb1 is not observed in an uninjured healthy cornea; but TGFb2 and TGFb3 are both detected in uninjured epithelium. Following an injury, extracellular TGFb1, TGFb2, and TGFb3 are all detected in subepithelial stromal tissue. In vitro cell or organ culture reveals that endogenous TGFb enhances cell migration of corneal epithelium. Such migrating epithelium lacks proliferative activity presumably due to inhibition of cell proliferation by TGFbl.
Unlike epidermis, loss of Smad3 does not affect re-epithelialization following corneal debridement in mice (S Saika, unpublished data, 2002). Nevertheless, this finding does not exclude the possibility that TGFb has an important function in modulation of corneal epithelial healing. Migrating epithelium upregulates phosphorylation of p38MAPK as early as 1 h postinjury. Organ-culture experiments using TGFb in the eye S Saika a TGFb-neutralizing antibody and the specific p38MAPK inhibitors, SB202190 and SB203580, revealed that TGFb/p38MAPK signal is required for epithelial cell migration and cessation of cell proliferation in migrating cells. 98 p38MAPK is known to modulate signaling cascades toward cell death or extracellular matrix expression, depending on cell types and kinds of stimuli. [99] [100] [101] Involvement of p38MAPK in cell migration has been observed in various cell types including corneal epithelium and cancer cell lines. However, it has not been fully elucidated whether or not p38MAPK's involvement in the cell migration is mediated by the phosphorylation of the linker regions of Smads2/3 or by its direct effect.
Stromal healing is initiated by inflammatory cells, that is, macrophages that activate mesenchymal cells via their expression of cytokines, including TGFb. The activated mesenchymal cells (keratocytes) express matrix components and various growth factors and contract the scarring stroma. VEGF, expressed in both invading macrophages and myofibroblasts, induces stromal neovascularization that also potentially causes corneal opacification.
Gene therapy for the treatment of corneal inflammation and fibrosis by targeting TGFb signaling
In corneas affected by chemical or thermal burn, or Stevens-Johnson's syndrome, various cytokines and growth factors, including interleukins, EGF, KGF, HGF, TNF a, TGFb, VEGF, and macrophage/ monocyte chemoattractant protein-1 (MCP-1), are believed to orchestrate cellular interactions and behaviors. The resulting pathological outcomes include scarring, conjunctivalization of the corneal surface and neovascularization. TGFb is chemotactic to macrophages and also activates stromal fibroblasts (keratocytes), leading to the generation of myofibroblasts and induction of other cytokines such as VEGF and MCP-1 which also have chemotactic activity. A key outcome is EMT-related tissue fibrosis. It is then reasonable to posit that an excessive wound healing reaction from inflammation and fibrobalst acticvation can also be a target of TGFb-inhibition therapy. Blocking the activity of TGFb by systemic expression of soluble TGFb receptor by adenoviral gene transfer results both in the suppression of liver fibrosis and acceleration of tissue repair in injured corneas in rats. 102, 103 Although these studies clearly demonstrate that endogenous TGFb is critical in the corneal tissue destruction after alkali exposure, blocking TGFb activity at the receptor level might potentially perturb healing of the corneal epithelial component by interfering with the p38MAPK activity that is required for epithelial cell migration. Smad3-null cutaneous repair is associated with hyperproliferation of epidermal keratinocytes and decreased chemotaxis of macrophages, resulting in acceleration of epithelial resurfacing and less scarring. This information prompted us to test whether blocking TGFb activity at the level of Smad signaling level might yield a more favorable result, since other TGFb signaling cascades would remain intact. Using a mouse corneal alkali burn model, we have shown that loss of Smad3 suppresses tissue destruction of the healing cornea in association with a reduction of macrophage infiltration, inhibition of myofibroblast generation, and suppression of growth factor expression. 104 Neovascularization also potentially impairs vision. Adenoviral gene transfer of mouse Smad7 cDNA has been used in the treatment of tissue fibrosis in several disease models, that is, bleomycin-induced pulmonary fibrosis, drug-induced liver fibrosis, or kidney fibrosis by unilateral ureteral obstruction. [105] [106] [107] Our results show that in mice Smad7 gene introduction by topical application suppresses scarring and neovascularization of the burned cornea, restoring its transparency.
104 Smad7 also suppressed generation of myofibroblasts, macrophage invasion, and the expression of wound healing-related cytokines. The effects were more marked than those seen in Smad3-null mice, probably because Smad7 also suppresses phosphorylated RelA of the NF-kB pathway, which leads to suppression of inflammation cascades. 104, 108 Signals derived from bone morphogenic protein-7 (BMP-7) are known to antagonize TGFb/Smad signal via Smad1/5/8 signal and induction of Id2 and Id3. We have shown that gene introduction of BMP-7 also has a therapeutic effect on an alkali burn in mice, although its efficacy is less than that of Smad7. 109 Unlike in an alkali-burned cornea, Stevens-Johnson's syndrome is an inflammatory ocular surface disease caused by an autoimmune mechanism. Nevertheless, the main component of the disease consists of inflammation and scarring that are similar to those seen in a burned eye. Thus, there is a possibility that interference of TGFb signaling might have a therapeutic effect on this disorder.
In conclusion, it is apparent that further understanding of the roles of TGFb in physiological and pathological processes of the eye is needed to develop new strategies in the treatment of ocular diseases; and Smad signaling is an important target for development of treatments of fibrosis-related diseases in the eye. 
